FoxWayne Enterprises Acquisition Corp. (FOXWU) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
1 ROCKEFELLER PLAZA NEW YORK, NY 10020 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2022 MRQ | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 41,574 | 2,966 | |||
| Cash and cash equivalent | 41,574 | 2,966 | |||
| Prepaid expense | 23,787 | ||||
| Total current assets: | 65,361 | 2,966 | |||
| Noncurrent Assets | |||||
| Asset, held-in-trust | 58,080,426 | ||||
| Deferred costs | 150,176 | ||||
| Total noncurrent assets: | 58,080,426 | 150,176 | |||
| TOTAL ASSETS: | 58,145,787 | 153,142 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,209,652 | 93,989 | |||
| Taxes payable | ✕ | 170,400 | 740 | ||
| Accounts payable | 115,238 | 32,102 | |||
| Accrued liabilities | 924,014 | 61,147 | |||
| Due to related parties | 132,700 | 40,510 | |||
| Total current liabilities: | 1,342,352 | 134,499 | |||
| Noncurrent Liabilities | |||||
| Liabilities, other than long-term debt | 3,605,500 | ||||
| Due to related parties | 100,000 | ||||
| Derivative instruments and hedges, liabilities | 3,505,500 | ||||
| Other undisclosed noncurrent liabilities | 2,012,500 | ||||
| Total noncurrent liabilities: | 5,618,000 | ||||
| Total liabilities: | 6,960,352 | 134,499 | |||
| Temporary equity, including noncontrolling interest | 58,075,000 | ||||
| Equity | |||||
| Equity, attributable to parent, including: | (6,889,565) | 18,643 | |||
| Additional paid in capital | 24,856 | ||||
| Accumulated deficit | (6,889,714) | (6,357) | |||
| Other undisclosed equity, attributable to parent | 149 | 144 | |||
| Total equity: | (6,889,565) | 18,643 | |||
| TOTAL LIABILITIES AND EQUITY: | 58,145,787 | 153,142 | |||
Income Statement (P&L) (USD)
| 9/30/2022 TTM | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|
| Operating expenses | (1,631,877) | |||
| Other undisclosed operating loss | (290,538) | |||
| Operating loss: | (1,922,415) | |||
| Nonoperating income (Investment Income, Nonoperating) | 5,426 | |||
| Loss from continuing operations before equity method investments, income taxes: | (1,916,989) | |||
| Other undisclosed income from continuing operations before income taxes | 871,006 | |||
| Loss from continuing operations before income taxes: | (1,045,983) | |||
| Income tax benefit | 402,568 | |||
| Loss from continuing operations: | (643,415) | |||
| Loss before gain (loss) on sale of properties: | ✕ | (643,415) | ✕ | |
| Net loss: | (643,415) | |||
| Other undisclosed net loss attributable to parent | (402,568) | |||
| Net loss available to common stockholders, diluted: | (1,045,983) | |||
Comprehensive Income (USD)
| 9/30/2022 TTM | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|
| Net loss: | (643,415) | |||
| Comprehensive loss, net of tax, attributable to parent: | (643,415) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.